Clinical trials · California
Alzheimer’s disease clinical trials in California
We’re tracking 68 recruiting alzheimer’s disease studies with a site in California — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in California
- NCT07224607Recruiting
Light therapy for early Alzheimer's disease
This study tests a type of light therapy (called transcranial photobiomodulation) to see if it can help people with early-stage Alzheimer's. It involves coming to Cedars-Sinai for weekly sessions over a period of time.
Los Angeles, CaliforniaAges 55–89 - NCT06159673RecruitingPhase 2/Phase 3
ACP-204 for Alzheimer's with psychosis
This study tests a new medicine called ACP-204 for people with Alzheimer's disease who also have psychosis (like seeing or hearing things that aren't real). It aims to see if the drug can help reduce these symptoms safely.
Anaheim, CaliforniaAges 55–95 - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Anaheim, CaliforniaAges 55–90 - NCT06947941RecruitingPhase 3
Testing karxt for psychosis in alzheimer's disease
This study tests whether a new medicine called KarXT can help with psychosis (hallucinations or delusions) in people with Alzheimer's disease. It aims to reduce troubling symptoms while being safe for older adults.
Chino, CaliforniaAges 55–90 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Anaheim, CaliforniaAges 55–90 - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Chino, CaliforniaAges 55–90 - NCT06540833RecruitingPhase 2
Study of a new drug for psychosis in people with Alzheimer's disease
This trial tests an experimental medication to reduce hallucinations and delusions in people who have Alzheimer's disease. It may help manage these symptoms and improve quality of life for patients and their caregivers.
Los Alamitos, CaliforniaAges 55 years+ - NCT06976203RecruitingPhase 3
Testing karxt for thinking problems in alzheimer's
This trial tests if a combination medicine, KarXT plus KarX-EC, can help with thinking and memory problems in people with mild to moderate Alzheimer's disease. It aims to see if the treatment is safe and effective.
Fullerton, CaliforniaAges 60–85 - NCT04804241RecruitingPhase 2
Senicapoc for early Alzheimer’s symptoms
This Phase 2 study tests whether the drug senicapoc can slow or improve symptoms in people with early Alzheimer’s disease or mild memory impairment. You would have a 50/50 chance of getting senicapoc or a placebo (inactive pill), along with regular study visits and testing.
Sacramento, CaliforniaAges 55–85 - NCT06023446Enrolling by invitation
Can eye photos detect early Alzheimer's disease?
This study uses a special camera (OCT) to take pictures of the retina (the back of your eye) to see if it can detect Alzheimer's disease very early. You may be eligible if you are either cognitively normal or have mild cognitive impairment, and have already had a test for Alzheimer's-related brain changes.
Sacramento, CaliforniaAges 50–89 - NCT06245031Enrolling by invitation
Long-term follow-up of sensory stimulation for Alzheimer's
This is a follow-up study for people who already completed the 12-month Hope Study (CA-0011). It tests long-term safety and effects of a gentle sensory stimulation device (light and sound) for Alzheimer's disease. You will continue using the device at home with a study partner.
Costa Mesa, CaliforniaAges 50–92 - NCT07780383RecruitingPhase 1
Single-dose study for healthy adults and early Alzheimer's participants
This trial tests a new investigational drug, BMS-986446, given as a single dose to healthy volunteers and multiple doses to people with early Alzheimer's disease. It aims to understand how the drug moves in the body, its safety, and whether it triggers an immune response, which could help guide future treatment for Alzheimer's.
Anaheim, CaliforniaAges 18–80 - NCT07459660Enrolling by invitationPhase 2
Long-term study of ML-007C-MA for Alzheimer's psychosis
This trial tests a long-term treatment (ML-007C-MA) for people with Alzheimer's disease who have psychosis. It is for those who already completed an earlier study with the same drug and may benefit from continuing it. The goal is to see if ongoing treatment is helpful and safe.
Anaheim, CaliforniaAges 55–91 - NCT07284472RecruitingPhase 2/Phase 3
Testing drugs for agitation in Alzheimer's disease
This trial tests two new drugs (EXV-802 and EXV-801) to see if they can safely reduce moderate to severe agitation in people with Alzheimer's dementia. If you or a loved one has Alzheimer's and has been experiencing significant agitation for at least two weeks, this study may be an option.
Murrieta, CaliforniaAges 55–90 - NCT07033494RecruitingPhase 2
Study of MK-2214 for early Alzheimer's disease
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Irvine, CaliforniaAges 50–85 - NCT06887192RecruitingPhase 2
Testing ML-007C-MA for Alzheimer's Psychosis
This trial tests a study drug called ML-007C-MA to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease who also have psychosis. If you or your loved one has Alzheimer's and has been experiencing false beliefs or seeing/hearing things that aren't there for at least two months, this study may be an option.
Anaheim, CaliforniaAges 55–90 - NCT07573982Recruiting
Ultrasound brain treatment for early memory loss
This study tests a special ultrasound treatment that may help clear harmful brain waste linked to Alzheimer's. You would receive the treatment in six short sessions, and the researchers will check your memory and brain health to see if it helps.
Stanford, CaliforniaAges 18 years+ - NCT05617014Enrolling by invitation
ADNI4 study for early Alzheimer’s with brain imaging tests
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
Walnut Creek, CaliforniaAges 55–90 - NCT06126224RecruitingPhase 3
Testing KarXT for Alzheimer's-related psychosis
This clinical trial tests an investigational oral medication called KarXT for treating psychosis (hallucinations or delusions) in people with Alzheimer's disease. The study aims to see if the drug can safely reduce these symptoms.
Anaheim, CaliforniaAges 55–90 - NCT05980949RecruitingPhase 3
Long-term safety study of KarXT for Alzheimer's psychosis
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
Anaheim, CaliforniaAges 55–90 - NCT06194799Enrolling by invitationPhase 3
Long-term ACP-204 for Alzheimer's psychosis
This study tests a long-term medicine (ACP-204) for people with Alzheimer's disease who also have psychosis (hallucinations or delusions). If you took part in the earlier ACP-204 study, this open-label extension lets you continue receiving the medicine to see how well it works over time.
Costa Mesa, CaliforniaAges 55–95 - NCT05511363RecruitingPhase 3
Study of a new medicine for psychosis in Alzheimer's disease
This trial tests a new drug called KarXT to see if it can safely reduce hallucinations and delusions in people with Alzheimer's disease. If you or a loved one has Alzheimer's and experiences these symptoms, this study might offer a new treatment option.
Encino, CaliforniaAges 55–90 - NCT07646054Enrolling by invitation
Lifestyle coaching for preventing Alzheimer's in APOE4 carriers
This study tests a digital lifestyle coaching program designed to help prevent Alzheimer's disease in people who carry the APOE4 genetic variant, which increases risk. Over one year, you'll get personalized health coaching through apps and possibly a smart ring to track your progress.
La Jolla, CaliforniaAges 60–80 - NCT07178210Recruiting
Robotic surgery for lymphatic drainage in Alzheimer's disease
This study tests a new robotic-assisted surgery to improve drainage of lymph fluid in the neck, which may help slow the progression of Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have specific biomarkers.
Palo Alto, CaliforniaAges 50 years+
Alzheimer’s disease trials by city in California
Where these studies are running in California
Institutions with a site for the recruiting alzheimer’s disease studies listed above.
- Advanced Research Center (ARC) · 6 studies
- Local Institution · 4 studies
- ATP Clinical Research · 3 studies
- Sunwise Clinical Research · 3 studies
- Clinical Site · 2 studies
- Inglewood Clinical · 2 studies
- Local Institution - 1001 · 2 studies
- Local Institution - 1031 · 2 studies
What taking part in a alzheimer’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Alzheimer’s disease trials in other states
Common questions
- Are there alzheimer’s disease clinical trials in California?
- Yes. We're currently tracking 68 recruiting alzheimer’s disease studies with a site in California, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alzheimer’s disease study in California?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in California to take part?
- Not necessarily. These studies have a site in California, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alzheimer’s disease studies open in California regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.